<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE OF REVIEW: <z:hpo ids='HP_0001634'>Mitral valve prolapse</z:hpo> is a common disorder with a strong hereditary component </plain></SENT>
<SENT sid="1" pm="."><plain>It is associated with important <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> requiring surgical repair and other clinical complications </plain></SENT>
<SENT sid="2" pm="."><plain>Genetic studies can provide clues to mechanism and therapy </plain></SENT>
<SENT sid="3" pm="."><plain>RECENT FINDINGS: Advances in phenotypic classification have led to linkage to sites on chromosomes 11, 13 and 16 and identification of the first mutation in familial <z:hpo ids='HP_0001634'>mitral valve prolapse</z:hpo> not related to connective tissue syndromes - an <z:hpo ids='HP_0001417'>X-linked</z:hpo> filamin A mutation </plain></SENT>
<SENT sid="4" pm="."><plain>New understanding of mechanism based on studies in a mouse Marfan model emphasize the dynamic interplay of differentiating cells and growth factors, with strong potential for therapy </plain></SENT>
<SENT sid="5" pm="."><plain>SUMMARY: This new knowledge brings us closer to the ultimate goal of preventing the progression of <z:e sem="disease" ids="C0264765,C0026265" disease_type="Disease or Syndrome" abbrv="">mitral valve disease</z:e> to the stage of clinical expression </plain></SENT>
</text></document>